Evidence map›Paper›PMID 41010570›Full record

ArticleJournal of clinical medicine2025

Long-Term Cardiorenal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Real-World Single-Center Experience.

Adnan Agha, Bachar Afandi, Saeed AlKaabi, Naser Abdulla Naser Salem Alshkeili, Mohammed Ali Alsharoon Alshemeili, Mohammed Mohammed Al Ghaithi, Mohammad Mohammed Hareb Alsaadi, Juma Alkaabi

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adnan AghaDepartment of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.ORCID 0000-0002-2704-8931
Bachar AfandiDepartment of Internal Medicine, Tawam Hospital, Al Ain P.O. Box 15258, United Arab Emirates.
Saeed AlKaabiDepartment of Internal Medicine, Tawam Hospital, Al Ain P.O. Box 15258, United Arab Emirates.ORCID 0009-0000-4870-2616
Naser Abdulla Naser Salem AlshkeiliDepartment of Internal Medicine, Tawam Hospital, Al Ain P.O. Box 15258, United Arab Emirates.ORCID 0009-0002-7364-9233
Mohammed Ali Alsharoon AlshemeiliDepartment of Internal Medicine, Tawam Hospital, Al Ain P.O. Box 15258, United Arab Emirates.
Mohammed Mohammed Al GhaithiDepartment of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.
Mohammad Mohammed Hareb AlsaadiDepartment of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.
Juma AlkaabiDepartment of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.ORCID 0000-0003-2477-0408

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ASCVD risk scorecanagliflozincardiorenal benefitscardiovascular risk reductiondapagliflozinempagliflozinsodium-glucose cotransporter-2 inhibitorstype 2 diabetes mellitusUnited Arab Emirates

Identifiers

PMID41010570
PMCPMC12470307

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.